Lp(a) HORIZON
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)

OBJECTIVE: To determine the effectiveness of pelacarsen in reducing risk of major adverse cardiovascular events (MACE) in patients with high lipoprotein(a) and established cardiovascular disease (CVD)

STUDY DESIGN: Phase 3, international, double-blind, randomized 1:1, placebo-controlled trial, N=8322

CONCLUSIONS: Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.

American Heart Association.

© 2026 American Heart Association. All rights reserved.
Results reflect the data available at the time of presentation.